Schmidt-Erfurth Ursula M, Michels Stephan, Kusserow Christine, Jurklies Bernhard, Augustin Albert J
University Eye Hospital, Luebeck, Germany.
Ophthalmology. 2002 Dec;109(12):2284-94. doi: 10.1016/s0161-6420(02)01454-9.
To document the anatomic and functional outcome of photodynamic therapy (PDT) in symptomatic choroidal hemangioma
Prospective, noncomparative, interventional case series.
Fifteen patients with circumscribed choroidal hemangioma of the posterior pole presenting with progressive vision loss caused by exudation into the macular area.
PDT using 6 mg/m(2) body surface area verteporfin and a light dose of 100 J/cm(2) at 692 nm was performed. One to four treatments with a single laser spot were applied in 6-week intervals. A standardized evaluation was provided before and at 6-week intervals after each treatment, at 3, 6, and 12 months, and a mean follow-up 19 months after the last application.
Functional tests included best-refracted visual acuity (Early Treatment of Diabetic Retinopathy Study criteria) and scanning laser scotometry. Anatomic results were documented by ophthalmoscopy, fluorescein/indocyanine green angiography, and ultrasonography.
A complete regression of the vascular mass was achieved in all eyes after the last course of one to four consecutive treatments. Tumors (mean height, 3.8 mm) responded with a reproducible decrease in size to each treatment, with the most intensive effect seen after the first application. Progressive occlusion of the angiomatous net without recanalization was documented angiographically. Two patients had stable vision with resolution of metamorphopsia; 13 patients demonstrated visual recovery. An overall visual acuity (VA) improvement of an average of 3 lines was documented, with a mean VA level of 20/125 before treatment and 20/80 after therapy. Visual fields showed withdrawal of central scotomas from the macula. No recurrence was seen during a follow-up for up to 50 months.
PDT using verteporfin offers a safe and effective option to treat choroidal hemangiomas. Complete anatomic regression with persistent absence of leakage is associated with substantial improvements in vision.
记录光动力疗法(PDT)治疗症状性脉络膜血管瘤的解剖学和功能学结果。
前瞻性、非对照、干预性病例系列研究。
15例后极部局限性脉络膜血管瘤患者,因黄斑区渗出导致视力进行性下降。
采用6mg/m²体表面积的维替泊芬进行PDT治疗,692nm波长下的光剂量为100J/cm²。每次治疗采用单个激光光斑,每6周进行1至4次治疗。在每次治疗前、治疗后6周间隔、3个月、6个月和12个月以及最后一次治疗后平均随访19个月时进行标准化评估。
功能测试包括最佳矫正视力(糖尿病视网膜病变早期治疗研究标准)和扫描激光视网膜视力计检查。通过检眼镜检查、荧光素/吲哚菁绿血管造影和超声检查记录解剖学结果。
在连续1至4次治疗的最后一个疗程后,所有患眼的血管团均完全消退。肿瘤(平均高度3.8mm)每次治疗后大小均有可重复的减小,首次治疗后效果最为明显。血管造影显示血管瘤网络逐渐闭塞且无再通。2例患者视力稳定,变形视消失;13例患者视力恢复。总体视力平均提高了3行,治疗前平均视力为20/125,治疗后为20/80。视野检查显示黄斑中心暗点消退。随访长达50个月未见复发。
使用维替泊芬的PDT为治疗脉络膜血管瘤提供了一种安全有效的选择。解剖学上的完全消退且持续无渗漏与视力的显著改善相关。